Bayer’s Ciprofloxacin DPI gets FDA orphan drug designation
Bayer is developing Ciprofloxacin DPI for NCFB patients with respiratory bacterial pathogens, including Pseudomonas aeruginosa, to reduce the frequency of acute exacerbations. These patients suffer from frequent severe
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.